In Ontario, Canada, the detection of ALK rearrangements in patients with NSCLC primarily utilizes immunohistochemistry (IHC) as the initial screening method, followed by confirmatory testing with more specific methods like FISH or next-generation sequencing [75]. This evidence concerns the gene ALK and non-small cell lung carcinoma.